JP2023502876A5 - - Google Patents
Info
- Publication number
- JP2023502876A5 JP2023502876A5 JP2022525630A JP2022525630A JP2023502876A5 JP 2023502876 A5 JP2023502876 A5 JP 2023502876A5 JP 2022525630 A JP2022525630 A JP 2022525630A JP 2022525630 A JP2022525630 A JP 2022525630A JP 2023502876 A5 JP2023502876 A5 JP 2023502876A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- approximately
- cancer
- seq
- pharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930512P | 2019-11-04 | 2019-11-04 | |
| US62/930,512 | 2019-11-04 | ||
| US202063080361P | 2020-09-18 | 2020-09-18 | |
| US63/080,361 | 2020-09-18 | ||
| PCT/EP2020/080892 WO2021089588A1 (en) | 2019-11-04 | 2020-11-04 | Her2/4-1bb bispecific fusion proteins for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023502876A JP2023502876A (ja) | 2023-01-26 |
| JP2023502876A5 true JP2023502876A5 (https=) | 2023-11-13 |
Family
ID=73598820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525630A Pending JP2023502876A (ja) | 2019-11-04 | 2020-11-04 | がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240166763A1 (https=) |
| EP (1) | EP4054718A1 (https=) |
| JP (1) | JP2023502876A (https=) |
| KR (1) | KR20220097952A (https=) |
| CN (1) | CN116348478A (https=) |
| AU (1) | AU2020379176A1 (https=) |
| CA (1) | CA3154881A1 (https=) |
| WO (1) | WO2021089588A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023541482A (ja) | 2020-09-18 | 2023-10-02 | ピエリス ファーマシューティカルズ ゲーエムベーハー | バイオマーカー法および使用法 |
| EP4644417A4 (en) * | 2022-12-30 | 2026-02-11 | Abclon Inc | AFFICORPS SPECIFICALLY BINDING TO CD137 AND ITS USE |
| CN116103244A (zh) * | 2023-04-12 | 2023-05-12 | 河北科技大学 | 一种单信号激活型til细胞的制备方法及应用 |
| KR20250148463A (ko) * | 2024-04-03 | 2025-10-14 | 주식회사유한양행 | 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| CN114573680A (zh) | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | Cd137特异性的蛋白 |
-
2020
- 2020-11-04 WO PCT/EP2020/080892 patent/WO2021089588A1/en not_active Ceased
- 2020-11-04 US US17/755,482 patent/US20240166763A1/en not_active Abandoned
- 2020-11-04 EP EP20815720.6A patent/EP4054718A1/en not_active Withdrawn
- 2020-11-04 KR KR1020227018948A patent/KR20220097952A/ko active Pending
- 2020-11-04 CA CA3154881A patent/CA3154881A1/en active Pending
- 2020-11-04 JP JP2022525630A patent/JP2023502876A/ja active Pending
- 2020-11-04 AU AU2020379176A patent/AU2020379176A1/en not_active Abandoned
- 2020-11-04 CN CN202080091568.2A patent/CN116348478A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11168144B2 (en) | Activatable anti-PDL1 antibodies, and methods of use thereof | |
| JP6961897B2 (ja) | 癌治療のためのｔ細胞活性化及び／又はチェックポイント阻害剤を組み合わせたペプチド及びペプチド模倣物 | |
| JP6767362B2 (ja) | リンパ球における阻害経路の中和 | |
| JP2023502876A5 (https=) | ||
| KR20210154266A (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| TW201902514A (zh) | Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2021510697A5 (https=) | ||
| US20230398229A1 (en) | Antibody drug conjugates comprising sting agonists, combinations and methods of use | |
| JP2021530428A (ja) | 頭頸部癌の処置 | |
| CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| WO2021182574A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| CN109793892B (zh) | 一种抗pd-1抗体在制备治疗食管癌的药物中的用途 | |
| JP2025508076A5 (https=) | ||
| KR102940576B1 (ko) | Api5 단백질에 특이적으로 결합하는 항체 | |
| US20250019462A1 (en) | Antibodies that specifically bind to api5 protein | |
| KR102926992B1 (ko) | Tctp에 특이적으로 결합하는 항체 및 이의 용도 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| HK40118760A (zh) | 特异性结合api5蛋白的抗体 | |
| KR20240143955A (ko) | Api5 에피토프 및 이에 특이적으로 결합하는 항체 | |
| WO2024149224A1 (zh) | Ccr8抗体的应用 | |
| JP2024540017A5 (https=) | ||
| TWI805542B (zh) | 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合 | |
| JP2023531189A5 (https=) | ||
| EA046745B1 (ru) | Способ лечения рака активируемым антителом против pdl1 |